Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies temozolomide to see how well it works compared to
selumetinib in treating patients with melanoma of the eye that has spread to other places in
the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Selumetinib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether temozolomide is more
effective than selumetinib in treating melanoma of the eye.